



Docket No. 296551US0PCT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Bertrand TAVITIAN, et al.

SERIAL NO: 10/593,256

GAU:

FILED: September 18, 2006

EXAMINER:

FOR: APTAMERS SELECTED FROM LIVE TUMOR CELLS AND THE USE THEREOF

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

COMMISSIONER FOR PATENTS
ALEXANDRIA, VIRGINIA 22313

SIR:

Applicant(s) wish to disclose the following information.

REFERENCES

The applicant(s) wish to make of record the references cited in the International Search Report and listed on the attached form PTO-1449. Copies of the listed references are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language references.

A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

RELATED CASES

Attached is a list of applicant's pending application(s), published application(s) or issued patent(s) which may be related to the present application. In accordance with the waiver of 37 CFR 1.98 dated September 21, 2004, copies of the cited pending applications are not provided. Cited published and/or issued patents, if any, are listed on the attached PTO form 1449.

A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

CERTIFICATION

Each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.

No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

DEPOSIT ACCOUNT

Please charge any additional fees for the papers being filed herewith and for which no check or credit card payment is enclosed herewith, or credit any overpayment to deposit account number 15-0030. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.
Norman F. OblonNorman F. Oblon
Registration No. 24,618

Customer Number

22850

Tel. (703) 413-3000
Fax. (703) 413-2220
(OSMMN 05/03)Surinder Sachar
Registration No. 34,423



SHEET 1 OF 1

Form PTO 1440
(Modified)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY DOCKET NO.
296551US0PCTSERIAL NO.
10/593,256

LIST OF REFERENCES CITED BY APPLICANT

APPLICANT
Bertrand TAVITIAN, et al.FILING DATE
September 18, 2006

GROUP

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
T.W.J	AA	5 580 737	12/03/96	POLISKY, Barry et al.			
T.W.J	AB	2003/049644	03/13/03	RABIN, ROSS et al.			
T.W.J	AC	6 280 932	08/28/01	PARMA, David H. et al.			
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						
	AM						
	AN						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES	NO
T.W.J	AO	2004/011680	02/05/04	WO		NO
T.W.J	AP	99/51777	10/14/99	WO		NO
	AQ					
	AR					
	AS					
	AT					
	AU					
	AV					

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)

T.W.J	AW	ICHIHARA, Masatoshi et al., "RET and neuroendocrine tumors", Cancer Letters, Vol. 204, No. 2, Pages 197-211, 2004.
T.W.J	AX	CHEN, Chi-hong B. et al., "Inhibition of heregulin signaling by an aptamer that preferentially binds to the oligomeric form of human epidermal growth factor receptor-3", Proceedings of The National Academy of Sciences of The United States of America, Vol. 100, No. 16, Pages 9226-9231, 2003.
	AY	
	AZ	
Examiner	/Teresa Wessendorf/	
	Date Considered 10/11/2010	

 Additional References sheet(s) attached

*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.